Management of Pulmonary Artery Issues in CVICU

Introduction to Management

The American Heart Association recommends a targeted approach focusing on pulmonary vasodilator therapy, hemodynamic optimization, and in severe cases, mechanical circulatory support for the management of pulmonary artery issues in the CVICU 1, 2

The American College of Cardiology suggests that direct measurement of central venous pressure via central line placement is necessary in critically ill patients with pulmonary artery issues, as non-invasive estimates may be misleading 3
The American Heart Association recommends considering pulmonary arterial catheterization (PAC) for accurate hemodynamic assessment, though it is not always required if central venous pressure and mixed oxygen saturation measurements are available 4
Continuous monitoring of the systemic-to-pulmonary vascular resistance ratio is crucial, as maintaining systemic vascular resistance (SVR) greater than pulmonary vascular resistance (PVR) is a major guideline for management 4, 5

The American College of Cardiology recommends selecting inotropes that have neutral or beneficial effects on pulmonary vascular resistance, including dobutamine, milrinone, and epinephrine 4, 2
Dobutamine is often preferred over milrinone due to its shorter half-life when there is risk of hypotension 2
The American Heart Association suggests considering vasopressin to offset potential drops in SVR, particularly in septic or liver patients with pulmonary hypertension, as vasopressin deficiency is common in these populations 4, 5

The American Thoracic Society recommends inhaled nitric oxide (iNO) for acute management as it decreases PVR, improves cardiac output, has a short half-life, and does not affect SVR 2
Upon weaning from iNO, the American College of Chest Physicians recommends starting or restarting a phosphodiesterase inhibitor as replacement therapy to prevent rebound pulmonary hypertension 2
For longer-term management, the American Heart Association suggests considering pulmonary arterial hypertension-specific targeted therapies 1
- Phosphodiesterase-5 inhibitors (sildenafil, tadalafil) 1
- Endothelin receptor antagonists (bosentan, ambrisentan) 1
- Prostacyclin pathway agonists (epoprostenol, treprostinil) 1

For patients with WHO functional class IV symptoms, the American College of Chest Physicians suggests continuous IV epoprostenol to improve functional class and exercise capacity 6
In patients unable to manage parenteral prostanoid therapy, the American Thoracic Society recommends combination therapy with an endothelin receptor antagonist and inhaled prostanoid 6

The American Thoracic Society recommends maintaining oxygen saturation >90% at all times to prevent hypoxia-induced increases in pulmonary vascular resistance 7, 2
If mechanical ventilation is required, the American College of Chest Physicians recommends employing a low-tidal volume strategy to minimize increases in right ventricular afterload 2
The American Association for Respiratory Care suggests keeping peak pressures <30 cmH₂O and limiting positive end-expiratory pressure to ≤10 cmH₂O when possible 2, 3
The American Thoracic Society recommends avoiding permissive hypercapnea as acidosis can acutely increase PVR 2

For patients with pulmonary hypertensive crisis, low cardiac output, or right ventricular failure despite optimal medical therapy, the American Heart Association recommends considering extracorporeal membrane oxygenation (ECMO) 1, 8
The Society of Critical Care Medicine suggests considering additional mechanical circulatory support options for left ventricular unloading if needed, such as intra-aortic balloon pump or Impella 9

The American Society of Anesthesiologists recommends that patients with pulmonary artery issues are at highest risk during procedures requiring significant volume shifts or prolonged anesthesia 2
For intubation, the American College of Cardiology suggests consulting an experienced cardiac anesthesiologist and using arterial line monitoring prior to the procedure 2
The American Society of Anesthesiologists recommends fiberoptic awake intubation to avoid overstimulation of sympathetic drive, which can increase PVR 2

The American College of Cardiology warns against misinterpreting hemodynamic data, particularly PAC data, which may lead to inappropriate therapeutic decisions 3, 5
The American Heart Association cautions against using static CVP values alone to guide fluid therapy without considering dynamic parameters 3
The American College of Chest Physicians advises against allowing PVR to exceed SVR, which can result in right ventricular ischemia 4
The American Thoracic Society recommends avoiding aggressive volume expansion in patients with right ventricular failure, which may worsen right ventricular function 3, 5